Precigen, a biotechnology company headquartered in Germantown, Maryland, focuses on synthetic biology technologies and develops therapies for urgent diseases. Founded in 2013, it operates through Biopharmaceuticals and Exemplar segments.
Phil Tennant bought 6,000 shares of PGEN on 29 September at $3.58 per share, worth a total of $21K. They now own 65,031 PGEN shares, or a 10% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.